CRLHIGH SIGNALFINANCIAL10-K

Charles River Laboratories experienced a dramatic financial deterioration with net income plunging from $22.2M profit to -$144.3M loss while simultaneously tripling share buybacks to $360.7M despite significantly weakened profitability.

This represents a concerning disconnect between capital allocation decisions and financial performance, as management aggressively bought back shares while the company swung to substantial losses. The combination of deteriorating operations (88.9% decline in operating income) and increased financial leverage (48.3% debt increase, 130.6% interest expense increase) suggests potential financial distress or major operational challenges that warrant immediate investor attention.

Comparing 2026-02-18 vs 2025-02-19View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows severe operational deterioration masked by revenue growth - while revenue increased 300% to $1.9B, operating income collapsed 88.9% and the company swung from $22.2M profit to -$144.3M loss. Despite this poor performance, management paradoxically increased share buybacks by 203% to $360.7M while debt grew 48.3% to $1.6B and interest expense more than doubled. This combination of deteriorating profitability, increased leverage, and aggressive share repurchases during losses signals potential financial mismanagement and creates significant risk for investors.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-750.1%
$22.2M→-$144.3M

Net income declined 750.1% — review whether driven by operations, interest costs, or non-recurring items.

Provision for Credit Losses
P&L
+304.7%
$1.7M→$6.7M

Credit loss provisions surged 304.7% — management flagging significant deterioration in loan quality ahead.

Revenue
P&L
+300.1%
$464.2M→$1.9B

Strong top-line growth of 300.1% — accelerating demand or successful expansion into new markets.

Share Buybacks
Cash Flow
+202.6%
$119.2M→$360.7M

Share repurchases increased 202.6% — management returning capital, signals confidence in intrinsic value.

Interest Expense
P&L
+130.6%
$59.3M→$136.7M

Interest expense surged 130.6% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
-88.9%
$227.3M→$25.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Debt
Balance Sheet
+48.3%
$1.1B→$1.6B

Debt increased 48.3% — substantial leverage increase; assess whether deployed for growth or covering losses.

Current Liabilities
Balance Sheet
+12.7%
$994.1M→$1.1B

Current liabilities rose 12.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-18
PRIOR — 2025-02-19
ADDED
As of January 24, 2026, there were 49,227,800 shares of the registrant s common stock outstanding, $0.01 par value per share.
In 2025, RMS accounted for 21.1% of our total revenue and approximately 4,140 of our employees, including approximately 190 science professionals with advanced degrees.
In 2025, our DSA segment represented 59.8% of our total revenue and employed approximately 11,760 of our employees including approximately 1,680 science professionals with advanced degrees.
In 2025, Manufacturing accounted for 19.1% of our total revenue and approximately 2,600 of our employees, including approximately 350 science professionals with advanced degrees.
In both cases - non-human primates we provide directly to clients and non-human primates which are utilized through our Safety Assessment services these large research models are sourced from Charles River internally or from Charles River audited and approved suppliers.
+7 more — sign up free →
REMOVED
As of January 25, 2025, there were 51,141,607 shares of the registrant s common stock outstanding, $0.01 par value per share.
For example, we may use forward-looking statements when addressing topics such as: our expectations regarding the availability of non-human primates and our ability to diversify our non-human primate (NHP) supply chain; the outcome of (1) the U.S.
In 2024, RMS accounted for 20.5% of our total revenue and approximately 4,100 of our employees, including approximately 200 science professionals with advanced degrees.
In 2024, our DSA segment represented 60.5% of our total revenue and employed approximately 12,100 of our employees including approximately 1,500 science professionals with advanced degrees.
In 2024, Manufacturing accounted for 19.0% of our total revenue from continuing operations and approximately 2,800 of our employees, including approximately 380 science professionals with advanced degrees.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →